Anavex Life Sciences Corp (AVXL)

[crescentmotor]

I suggest you are using the term blinded in a way that is not its usual meaning.

Yes--I can see why that caused confusion. Let me try this again. It is my understanding that SAVA has disclosed that after the 12 months dosing in its Phase III RETHINK trial (and also for its 18 month REFOCUS trial), patients wanting to participate are continuing in an OLE phase. Those patients are being retested upon beginning the OLE to establish new baseline characteristics. By doing that SAVA is able to continue measuring the efficacy of Simufilam beyond the initial Phase III 12 month treatment period (18 months for the REFOCUS trial). Do we know whether or not AVXL is following that same approach in its OLE program following the Phase II/III trial? In other words, will AVXL have additional Blarcamesine efficacy data to report from its OLE patients? I surely hope so but it would be nice if that could be confirmed.